Genetic Testing for Cancer Risk: Is the Community Willing to Pay for It?

Aizuddin, Azimatun Noor; Ramdzan, Abdul Rahman; Omar, Sharifah Azween Syed; Mahmud, Zuria; Latiff, Zarina Abdul; Amat, Salleh; Teik, Keng Wee; Siew, Ch'ng Gaik; Rais, Haniza; Aljunid, Syed Mohamed

doi:10.3390/ijerph18168752

Cited by 6 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of this study are in alignment with a prior investigation concerning prostate cancer [25]. However, research in distinct domains, such as breast cancer screening [39] and genetic testing for cancer risk [50], reveals a inconsistence result where having insurance coverage exerts a positive significant on individuals' willingness to pay (WTP). This discrepancy underscores the necessity to recognize the diverse impacts of insurance coverage on various healthcare services.…”

Section: Factors Affecting the Level Of Wtpsupporting

confidence: 81%

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

Farabi,

Moradi,

Ahmadzadeh

et al. 2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Introduction This study investigates Iranian men’s willingness to pay (WTP) for prostate cancer (PCa) screening and influencing factor, along with the impact of information. Method We assessed preferences for prostate cancer screening in 771 Iranian men aged 40 and above using an internet-based questionnaire survey. Participants received basic and complementary information, and their willingness to pay was determined through a payment card approach. A Wilcoxon test assessed the impact of information. We also analyzed prostate cancer screening demand and employed Heckman's two-step model to evaluate factors influencing the willingness to pay. Additionally, reasons for unwillingness to pay were explored. Results Willingness to pay significantly decreased with complementary information relative to basic information (16.3$ vs 17.8$). Heckman model, using WTP based on basic information shows age, education, and monthly household expenditure positively influenced the decision to pay. In contrast, health status, expectations of remaining life and prostate problems history positively affect amount of WTP for PCa screening, and insurance coverage has a negative impact on it. Majority of respondents (91%) supported PCa screening, with 82% expressing a willingness to pay. Common reasons for not paying include seeing screening as a public good (43%), financial constraints (35%), and having insurance (20%). The screening demand is price-sensitive. Conclusion The basic mindset of Iranian men exaggerates the risk of prostate cancer. Reduced willingness to pay after receiving information reassures the reliability of their financial expectation. Taking into account the factors that influence PCa screening is essential for accurate planning and the successful implementation of this program.

show abstract

Section: Factors Affecting the Level Of Wtpsupporting

confidence: 81%

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

Farabi,

Moradi,

Ahmadzadeh

et al. 2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

show abstract

“…Cost has been identified as a critical barrier in opting for genetic testing and counselling in several studies conducted in the regions that were surveyed in this study ( 7 – 9 , 11 ). Similar observations were made in this survey as well.…”

Section: Discussionmentioning

confidence: 99%

MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer

Powell,

Artigas,

Borovova

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveGenetic testing and counselling are critical in assessing breast cancer risk and tailoring treatment strategies. However, several barriers hinder patients from opting for genetic testing/counselling, leading to fewer than one-third of patients undergoing testing and even fewer being offered counselling. A granular understanding of these barriers is essential in overcoming them.MethodsA multinational survey developed by patient authors was conducted in 9 countries, to identify the specific local/regional barriers. The survey question pathway was individualized, based on responses to prior questions. Percentage responses to a response option were calculated based on the total number of respondents to that question. Chi-square tests were used to assess the significance of the results, if applicable.ResultsThe final analysis set (FAS) included 1,176 respondents, with a subset of this responding to all questions. In the FAS, 63% of respondents had undergone testing. Among those who got tested, 70% were offered testing. Among untested respondents, only 40% were offered the test but eventually did not get tested. In the tested population, 44% received counselling, which was significantly higher than 7% (p<0.00001) in the untested group. Among those reporting on awareness, 71% reported awareness level between ‘very low’ and ‘moderate’ prior to cancer diagnosis. Most respondents (71%) agreed that all breast cancer patients should undergo testing before treatment initiation. However, Asian patients were less likely to endorse this view compared to respondents from other regions (25% vs ≥50%; p<0.00001). A higher proportion of tested respondents were ‘very willing’ to get their family members tested (44%) versus untested respondents (11%), with relatively higher willingness among Australian (77%) and Russian respondents (56%), the regional variation being statistically significant (p<0.00001).ConclusionsCritical gaps remain in the access, awareness and perceived value of genetic testing and counselling, with regional variance or difference between the tested and untested groups. Most patients are not offered counselling, which may be associated with the low uptake of testing. Strategic action is needed to drive policy-shaping and improve access to testing and counselling, including raising patient awareness and improving patient experience for better treatment outcomes.

show abstract

“…Health professionals including radiologists and breast cancer specialists play important roles with respect to the implementation and sustainability of a screening programme and guidelines [24,18] (Malaysian Ringgit, MYR 200.00), which included women who indicated that they would be willing to share the cost with a health insurance company [32]. The estimated cost to the MOH Malaysia for providing breast cancer genetic testing is USD 325 (MYR1500) [34], which is much higher than the amount that is indicated in the willingness-to-pay study.…”

Section: Assessment Of Risk For Breast Cancer and Screening Highrisk ...mentioning

confidence: 99%

“…Compared to countries with more developed economies and health systems, Malaysian women were less informed about genetic testing and how this test information can be used to predict cancer risk [ 31 ]. Despite the lack of information, there appeared to be a moderate level of interest among women to take a genetic test, ranging from 41.7% (age 40 to 60 years) [ 32 ] to 67.9% (age 19 to 26 years ) [ 31 ]. Regarding healthcare professionals, nurses reported positive attitudes about testing and were recorded as having adequate knowledge about BRCA genetic testing in Malaysia [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

“…Regarding healthcare professionals, nurses reported positive attitudes about testing and were recorded as having adequate knowledge about BRCA genetic testing in Malaysia [ 33 ]. Indeed, willingness to pay for genetic testing in the general population was reported to be a median of USD 48.31 (Malaysian Ringgit, MYR 200.00), which included women who indicated that they would be willing to share the cost with a health insurance company [ 32 ]. The estimated cost to the MOH Malaysia for providing breast cancer genetic testing is USD 325 (MYR1500) [ 34 ], which is much higher than the amount that is indicated in the willingness-to-pay study.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk-Stratified Breast Cancer Screening in Malaysia: Challenges and Opportunities

Htay,

Su,

Donnelly

2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Breast cancer in MalaysiaBreast cancer is the commonest cancer in the Malaysian population and approximately one out of five cancer patients have breast cancer (19% of all cancer) [1]. Age-standardised incidence rates of breast cancer among Malaysian women have been increasing and were 34.1 in 2016 [1]. Late-stage diagnosis has been increasing also -the most recent report estimated that 47.9% of women were diagnosed at Stage III and IV even though cancer screening, prevention, and control programmes have been implemented in Malaysia [1][2][3]. Furthermore, the onset of breast cancer among Malaysian women is early and approximately half of patients are diagnosed before the age of 50 years [4].

show abstract

Genetic Testing for Cancer Risk: Is the Community Willing to Pay for It?

Cited by 6 publications

References 35 publications

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer

Risk-Stratified Breast Cancer Screening in Malaysia: Challenges and Opportunities

Contact Info

Product

Resources

About